Anaplastic Large-cell Lymphoma
Showing 1 - 5 of 5
DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- +4 more
- EPOCH
- Rituximab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma Trial in Worldwide (brentuximab vedotin, doxorubicin,
Completed
- Anaplastic Large-Cell Lymphoma
- +2 more
- brentuximab vedotin
- +4 more
-
Gilbert, Arizona
- +143 more
Nov 1, 2021
Hodgkin Lymphoma, Anaplastic Large-cell Lymphoma Trial in Belgium, Lithuania, Spain (brentuximab vedotin, Brentuximab vedotin
Completed
- Hodgkin Lymphoma
- Anaplastic Large-cell Lymphoma
- brentuximab vedotin
- Brentuximab vedotin and rifampicin
-
Brussels, Belgium
- +5 more
Mar 30, 2016
Anaplastic Large-Cell Lymphoma Trial in United States (SGN-30 (anti-CD30 mAb))
Completed
- Anaplastic Large-Cell Lymphoma
- SGN-30 (anti-CD30 mAb)
-
Birmingham, Alabama
- +17 more
Dec 17, 2014
Anaplastic Large-Cell Lymphoma Trial in New York (Denileukin Diftitox, Denileukin diftitox, ifosfamide, cyclophosphamide,
Withdrawn
- Anaplastic Large-Cell Lymphoma
- Denileukin Diftitox
- Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
-
New York, New YorkColumbia University Medical Center
May 14, 2013